Epistasis buffers the fitness effects of rifampicin- resistance mutations in Pseudomonas aeruginosa

Evolution

Volumn 65, Issue 8, 2011, Pages 2370-2379

  Hall, Alex R ^a   Maclean, R Craig ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibiotic resistance; Compensatory adaptation; Epistasis; Experimental evolution; rpoB

Indexed keywords

ANTIINFECTIVE AGENT; DNA DIRECTED RNA POLYMERASE; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT;

ADAPTATION; ANTIBIOTIC RESISTANCE; BACTERIUM; EPISTASIS; EXPERIMENTAL STUDY; FITNESS; LIFE HISTORY TRAIT; MUTATION; REPRODUCTIVE COST;

ADAPTATION; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; EVOLUTION; GENETIC EPISTASIS; GENETICS; MUTATION; PSEUDOMONAS AERUGINOSA; REPRODUCTIVE FITNESS;

ADAPTATION, PHYSIOLOGICAL; ANTI-BACTERIAL AGENTS; BIOLOGICAL EVOLUTION; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MICROBIAL; EPISTASIS, GENETIC; GENETIC FITNESS; MUTATION; PSEUDOMONAS AERUGINOSA; RIFAMPIN;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

EID: 79960836520     PISSN: 00143820     EISSN: 15585646     Source Type: Journal    
DOI: 10.1111/j.1558-5646.2011.01302.x     Document Type: Article

References (54)

1. Anderson, J. B. 2005. Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat. Rev. Microbiol. 3:547-556.
2. Andersson, D. I. 2003. Persistence of antibiotic resistant bacteria. Curr. Opin. Microbiol. 6:452-456.
3. Andersson, D. I. 2006. The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9:461-465.
4. Andersson, D. I., and D. Hughes. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
5. Björkman, J., I. Nagaev, O. G. Berg, D. Hughes, and D. I. Andersson. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482.
6. Campbell, E. A., N. Korzheva, A. Mustaev, K. Murakami, S. Nair, A. Goldfarb, and S. A. Darst. 2001. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 104:901-912.
7. Davis, B. H., A. F. Y. Poon, and M. C. Whitlock. 2009. Compensatory mutations are repeatable and clustered within proteins. Proc. R. Soc. Lond. B 276:1823-1827.
8. Dean, A. M., D. E. Dykhuizen, and D. L. Hartl. 1986. Fitness as a function of beta-galactosidase activity in Escherichia coli. Genet. Res. 48:1-8.
9. DePristo, M. A., D. M. Weinreich, and D. L. Hartl. 2005. Missense meanderings in sequence space: a biophysical view of protein evolution. Nat. Rev. Genet. 6:678-687.
10. Drake, J. W. 1991. A constant rate of spontaneous mutation in DNA-based microbes. Proc. Natl. Acad. Sci. USA 88:7160-7164.
11. Dykhuizen, D. E., and A. M. Dean. 1990. Enzyme activity and fitness-evolution in solution. Trends Ecol. Evol. 5:257-262.
12. Dykhuizen, D. E., A. M. Dean, and D. L. Hartl. 1987. Metabolic flux and fitness. Genetics 115:25-31.
13. Gagneux, S., C. D. Long, P. M. Small, T. Van, G. K. Schoolnik, and B. J. M. Bohannan. 2006. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312:1944-1946.
14. Garibyan, L., T. Huang, M. Kim, E. Wolff, A. Nguyen, T. Nguyen, A. Diep, K. B. Hu, A. Iverson, H. J. Yang. 2003. Use of the rpoB gene to determine the specificity of base substitution mutations on the Escherichia coli chromosome. DNA Repair 2:593-608.
15. Gros, P. A., H. Le Nagard, and O. Tenaillon. 2009. The evolution of epistasis and its links with genetic robustness, complexity and drift in a phenotypic model of adaptation. Genetics 182:277-293.
16. Hall, A. R., V. F. Griffiths, R. C. MacLean, and N. Colegrave. 2010. Mutational neighbourhood and mutation supply rate constrain adaptation in Pseudomonas aeruginosa. Proc. R. Soc. Lond. B 277:643-650.
17. Jin, D. J., and C. A. Gross. 1989. Characterization of the pleiotropic phenotypes of rifampin-resistant Rpob mutants of Escherichia coli. J. Bacteriol. 171:5229-5231.
18. m for purine nucleotides during transcription elongation. J. Biol. Chem. 266:14478-14485.
19. Jin, D. J., W. A. Walter, and C. A. Gross. 1988. Characterization of the termination phenotypes of rifampicin-resistant mutants. J. Mol. Biol. 202:245-253.
20. Korona, R. 1999. Genetic load of the yeast Saccharomyces cerevisiae under diverse environmental conditions. Evolution 53:1966-1971.
21. Kugelberg, E., S. Lofmark, B. Wretlind, and D. I. Andersson. 2005. Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother.55:22-30.
22. Landick, R., J. Stewart, and D. N. Lee. 1990. Amino acid changes in conserved regions of the beta-subunit of Escherichia coli RNA polymerase alter transcription pausing and termination. Genes Develop. 4:1623-1636.
23. Lenski, R. E., M. R. Rose, S. C. Simpson, and S. C. Tadler. 1991. Long-term experimental evolution in Escherichia coli 1. Adaptation and divergence during 2, 000 generations. Am. Nat. 138:1315-1341.
24. Lindgren, P. K., L. L. Marcusson, D. Sandvang, N. Frimodt-Møller, and D. Hughes. 2005. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob. Agents. Chemother. 49:2343-2351.
25. Luciani, F., S. A. Sisson, H. L. Jiang, A. R. Francis, and M. M. Tanaka. 2009. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 106:14711-14715.
26. MacLean, R. C., and G. Bell. 2002. Experimental adaptive radiation in Pseudomonas. Am. Nat.160:569-581.
27. MacLean, R. C., and A. Buckling. 2009. The distribution of fitness effects of beneficial mutations in Pseudomonas aeruginosa. PLoS Genet. 5:e1000406.
28. MacLean, R. C., G. G. Perron, and A. Gardner. 2011. Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa. Genetics 186:1345-1354.
29. Maisnier-Patin, S., and D. I. Andersson. 2004. Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155:360-369.
30. Maisnier-Patin, S., W. Paulander, A. Pennhag, and D. I. Andersson. 2007. Compensatory evolution reveals functional interactions between ribosomal proteins S12 L14 and L19. J. Mol. Biol. 366:207-215.
31. Marcusson, L. L., N. Frimodt-Møller, and D. Hughes. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS. Pathogens 5:e1000541.
32. Mariam, D. H., Y. Mengistu, S. E. Hoffner, and D. I. Andersson. 2004. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob. Agents. Chemother. 48:1289-1294.
33. Nagaev, I., J. Björkman, D. I. Andersson, and D. Hughes. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439.
34. Nilsson, A. I., A. Zorzet, A. Kanth, S. Dahlstrom, O. G. Berg, and D. I. Andersson. 2006. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA 103:6976-6981.
35. O'Neill, A. J., T. Huovinen, C. W. G. Fishwick, and I. Chopra. 2006. Molecular genetic and structural modeling studies of Staphylococcus aureus RNA polymerase and the fitness of rifampin resistance genotypes in relation to clinical prevalence. Antimicrob. Agents. Chemother. 50:298-309.
36. Paulander, W., S. Maisnier-Patin, and D. I. Andersson. 2007. Multiple mechanisms to ameliorate the fitness burden of mupirocin resistance in Salmonella typhimurium. Mol. Microbiol. 64:1038-1048.
37. Perkins, A. E., and W. L. Nicholson. 2008. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. J. Bacteriol. 190:807-814.
38. Perron, G. G., A. R. Hall, and A. Buckling. 2010. Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. Am. Nat. 176:303-311.
39. Petersen, A., F. M. Aarestrup, and J. E. Olsen. 2009. The in vitro fitness cost of antimicrobial resistance in Escherichia coli varies with the growth conditions. FEMS Microbiol. Lett. 299:53-59.
40. Phillips, P. C. 2008. Epistasis-the essential role of gene interactions in the structure and evolution of genetic systems. Nat. Rev. Genet. 9:855-867.
41. Ramaswamy, S., and J. M. Musser. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber. Lung. Dis. 79:3-29.
42. Reynolds, M. G. 2000. Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156:1471-1481.
43. Rozen, D. E., L. McGee, B. R. Levin, and K. P. Klugman. 2007. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents. Chemother. 51:412-416.
44. Sandgren, A., M. Strong, P. Muthukrishnan, B. K. Weiner, G. M. Church, and M. B. Murray. 2009. Tuberculosis drug resistance mutation database. PLoS. Medicine. 6:132-136.
45. Shabalina, S. A., L. Y. Yampolsky, and A. S. Kondrashov. 1997. Rapid decline of fitness in panmictic populations of Drosophila melanogaster maintained under relaxed natural selection. Proc. Natl. Acad. Sci. USA 94:13034-13039.
46. Singer, M., D. J. Jin, W. A. Walter, and C. A. Gross. 1993. Genetic-evidence for the interaction between cluster-I and cluster-III rifampicin resistant mutations. J. Mol. Microbiol. 231:1-5.
47. Szafraniec, K., R. H. Borts, and R. Korona. 2001. Environmental stress and mutational load in diploid strains of the yeast Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 98:1107-1112.
48. Tokuriki, N., F. Stricher, J. Schymkowitz, L. Serrano, and D. S. Tawfik. 2007. The stability effects of protein mutations appear to be universally distributed. J. Mol. Microbiol. 369:1318-1332.
49. Trindade, S., A. Sousa, K. B. Xavier, F. Dionisio, M. G. Ferreira, and I. Gordo. 2009. Positive epistasis drives the acquisition of multidrug resistance. PLoS. Genetics. 5:e1000578.
50. Trinh, V., M. F. Langelier, J. Archambault, and B. Coulombe. 2006. Structural perspective on mutations affecting the function of multisubunit RNA polymerases. Microbiol. Mol. Biol. Rev. 70:12-36.
51. Ward, H., G. G. Perron, and R. C. Maclean. 2009. The cost of multiple drug resistance in Pseudomonas aeruginosa. J. Evol. Biol. 22:997-1003.
52. Weinreich, D. M., R. A. Watson, and L. Chao. 2005. Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59:1165-1174.
53. Weinreich, D. M., N. F. Delaney, M. A. DePristo, and D. L. Hartl. 2006. Darwinian evolution can follow only very few mutational paths to fitter proteins. Science 312:111-114.
54. Wilke, C. O., and C. Adami. 2001. Interaction between directional epistasis and average mutational effects. Proc. R. Soc. Lond. B. 268:1469-1474.